Patent ID: 7138396
Filing Date: 2006-11-21
Classification: A61P,C07D

Abstract:
1. A method of treating androgen-dependent diseases selected from the group consisting of prostate cancer, benign prostatic hyperplasia, prostatic intraepithelial neoplasia, hirsutism, acne, androgenic alopecia and polycystic ovary syndrome comprising administering to a mammal in need thereof an effective amount of a compound of the formula (I): or a pharmaceutically acceptable salt thereof wherein, R a) halogen; b) —OCF c) —CF d) —CN; e) alkyl or R f) heteroalkyl or R g) aryl or R h) heteroaryl or R i) arylalkyl or R j) heteroarylalkyl or R k) hydroxy; l) alkoxy; m) aryloxy; n) —SO o) —NR p) —N(R q) methylenedioxy; r) difluoromethylenedioxy; s) trifluoroalkoxy; t) —SCH u) —SO R R provided that when Z and/or X is N, then R 4 , R 5 , R 7 and R 8 are not OH, OR 14 , —NR 11 R 12 , or —N(R 11 )C(O)R 13 ; R R —N(R 11 )C(O)R 13 ; R R R R R R either X═Z═N, or X═Z═C or X is C and Z is N; wherein the term “heteroaryl” refers to 5- to 10-membered single or benzofused aromatic ring consisting of 1 to 3 heteroatoms independently selected from the group consisting of O, S and N, provided that the rings do not possess adjacent oxygen and/or sulfur atoms, wherein said heteroaryl can be unsubstituted or substituted with one, two, or three substituents independently selected from lower alkyl, halo, cyano, nitro, haloalkyl, hydroxy, alkoxy, carboxy, carboxyalkyl, carboxamide, mercapto, amino, alkylamino and dialkylamino; the term “heteroarylalkyl” refers to a heteroaryl group bonded through an alkyl group; the term “heterocycloalkyl” refers to a non-aromatic heterocyclic ring of 3–7 atoms containing 1–3 heteroatoms selected from N, O and S; and the term “heteroalkyl” refers to an alkyl group containing at least one heteroatom; in combination with at least one anti-androgenic agent.